Reports Q1 revenue $68M, consensus $72.22M. "We are confident in the strength of Ocaliva’s market position and the long-term opportunity with our foundational PBC business, as evidenced by double-digit sales growth for the third consecutive quarter and clinical development progress for the OCA-bezafibrate fixed-dose combination," said Jerry Durso, President and Chief Executive Officer of Intercept. "In NASH, we are very focused on the upcoming Advisory Committee Meeting to review our new drug application in pre-cirrhotic fibrosis due to NASH. We look forward to this important step to discuss the strong and confirmed antifibrotic effect of OCA, as well as its monitorable and manageable safety profile. In parallel, we continue to make significant progress as we prepare to successfully launch a potential first-to-market therapy for NASH. Our strong financial position gives us the optionality to execute on upcoming milestones, drive long-term growth and develop innovative new medicines such as the OCA-bezafibrate combination, which we believe has the potential to establish new best-in-class clinical benefits for patients living with PBC," Durso continued.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ICPT:
- Intercept Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Update on Commercial Launch Strategy for NASH
- Intercept Announces New Data to be Presented at The European Association for the Study of the Liver (EASL) Congress 2023 and Provides Update on OCA-bezafibrate Fixed-Dose Combination (FDC) Development Program
- Is ICPT a Buy, Before Earnings?
- Piper Sandler pharmaceuticals analysts to hold analyst/industry conference call
- Intercept to Announce First Quarter 2023 Financial Results and Provide Update on Commercial Launch Strategy for NASH on April 27, 2023